Apoteket AB expands the distribution of VagiVital® (English translation of the press release of yesterday)

Peptonic Medical AB (publ) (‘Peptonic’ or ‘Company’) today announced that during May Apoteket AB will expand the distribution of Peptonic’s self-care product VagiVital® from today’s 30 to 250 of its retail pharmacy shops in Sweden.

Since February this year, VagiVital® can also be purchased on the Apotektet AB’s webshop (www.apoteket.se). In connection with this distribution expansion, Peptonic has received a purchase order from Apoteket worth 440,000 SEK.

In addition to Apoteket AB, VagiVital® can be purchased from the webshops of Apoteket Hjärtat (www.apotekhjartat.se) and Kronans Apotek (www.kronansapotek.se) , and on www.apotea.se, www.meds.se, www.apotek365.se and www.apohem.se.

In April this year, Orion Pharma OY launched VagiVital® in Finland under its own trade mark, Femisan Vital.

Johan Inborr, CEO
Mobile: + 46 708 853 893
E-mail: johan.inborr@peptonicmedical.se

About VagiVital®

VagiVital®is a patent pending hormone free self-care product for the treatment of vaginal atrophy and vaginal dryness. The product has been tested in randomised clinical studies (vaginal atrophy) with very positive results both for objective (vaginal pH and proportion of superficial cells in the vaginal mucosa) and subjective (most bothersome symptoms, such as vaginal dryness, vaginal irritation/itching, dyspareunia and dysuria) parameters. The magnitude of symptom relief is on par with that demonstrated with e.g. prescription estrogen based products on the market today. It was very well tolerated and caused no serious adverse effects. 

VagiVital®was launched in Sweden as a non-prescription self-care product in July 2018 (see www.vagivital.com). 

About Peptonic Medical

Peptonic Medical is an innovative Swedish medical development company. Its vision is to offer safe and effective treatments and relief for women specific diseases and medical conditions.

VagiVital®is a registered trademark of Peptonic Medical. The product is hormone free and is being commercialised for the non-prescription use for the treatment of vaginal atrophy (VA) and vaginal dryness. The pipeline of Peptonic Medical also includes Vagitocin®, which is an oxytocin-based vaginal gel for the treatment of VA. This product candidate is in clinical development phase 2. The development of Vagitocin® is on hold pending additional data on i.a. the mechanism of action.

Since July 2014, the Peptonic Medical share has been traded on the Spotlight Stock Exchange (www.spotlightstockmarket.com, ticker: PMED) in Stockholm, Sweden. 

More information about the company »